FILING ANALYSIS · THURSDAY, NOVEMBER 12
BlossomHill Therapeutics, Inc. BLSM — 8-K: Results of Operations and Financial Condition
neutral
BlossomHill Therapeutics reported a net loss of $24.0 million and cash and cash equivalents of $224.9 million as of September 30, 2026, with no significant quantified surprises in the announcement, and the company's recent progress and upcoming milestones are already priced in.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →